Quantcast

Latest Pyrroles Stories

2014-08-12 08:30:30

SAN DIEGO, Aug. 12, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that K. Peter Hirth, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Hirth is an industry leader and innovator with over 30 years of biotechnology and pharmaceutical discovery and development experience. A pioneer in the field of personalized medicine, Dr. Hirth led the organizations that developed both Sutent(®) and Zelboraf(®);...

2014-08-11 12:26:57

Significant Opportunity Exists for New Therapies to Treat GIST, Particularly those for Treating Unresectable and/or Metastatic Disease in Later-Line Settings BURLINGTON, Mass., Aug. 11, 2014 /PRNewswire/ -- Decision Resources Group finds that the treatment landscape of gastrointestinal stromal tumors (GIST) will not change dramatically through 2023 as no new therapies are expected to launch for this indication. Treatment of GIST is largely dependent on tumor size, location and growth rate and...

2014-04-22 12:31:30

LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H1, 2014 http://www.reportbuyer.com/pharma_healthcare/research_r_d/clinical_trials/gastrointestinal_stromal_tumor_gist_global_clinical_trials_review.html Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H1, 2014 SummaryGlobalData's clinical trial report, "Gastrointestinal Stromal Tumor (GIST) Global...

2014-02-20 04:21:29

WHIPPANY, N.J., Feb. 20, 2014 /PRNewswire/ -- Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga(®) (regorafenib) tablets in colorectal cancer (CRC) patients with resected liver metastases. The randomized, double-blind, placebo-controlled Phase III trial is designed to determine the effects of Stivarga as adjuvant treatment following surgical removal of liver metastases.(1) "Patients with more advanced colorectal cancer often...

2013-12-05 23:23:04

A recent study featured in the latest issue of The Oncologist shows that active smoking greatly diminishes patients’ chances of responding to chemotherapeutic treatment for renal cell carcinoma (RCC). The research team, jointly led by Dr. Michael Carducci from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD and Dr. Daniel Keizman from the Sackler School of Medicine at Tel Aviv University, conducted a retrospective analysis exploring the association of...

2013-03-18 12:28:02

Markers such as CA9, CD31, CD34 and VEGFR1/2 in the primary tumors might serve as predictors of a good response to a sunitinib treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to a new study to be presented at the 28th Annual EAU Congress currently on-going in Milan. "The inactivation of the von Hippel-Lindau gene (VHL) is a common event in ccRCC and finally leads to the induction of HIF1α target genes such as CA9 and VEGF," write the...